VistaGen Therapeutics, Inc. Common Stock, also called VistaGen Therapeutics, is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders. Read More The company's portfolio includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that the company is currently preparing for Phase III clinical trial for social anxiety disorder (SAD), PH10, a neuroactive nasal spray that the company is planning for Phase 2b development as a stand-alone treatment for major depressive disorder (MDD), and AV-101 which the Company is developing for the treatment of major depressive disorder (MDD), suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID) and epilepsy. The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA. The listed name for VTGN is VistaGen Therapeutics, Inc. Common Stock.